

**IMMUNALL SCIENCE INC.  
(the “Corporation”)**

**Default Status Report**

Immunall Science Inc. (the “Corporation”) is giving this Default Status Report under the provisions of CSA Staff Notice 57-301. The Corporation is not able to file on time its audited financial statements for the year ended December 31, 2007. The Corporation is unable to file these financial statements on time as a result of delays in completion of its audit due to a significant restructuring of its business and corporate structure shortly prior to December 31, 2007. The Corporation anticipates being able to file these financial statements by June 29, 2008.

The Corporation is not the subject of any insolvency proceeding and, as a result, is not subject to any obligations to provide information to its creditors. The Corporation will file material change reports containing the same information, if any, it provides to creditors at the same time the information is provided to creditors throughout the period in which it is in default. There have been no material changes in the Corporation’s business or fiscal position during the past two weeks.

The filing deadline for the Corporation’s audited financial statements for the period ended December 31, 2007 is April 29, 2008. If 2 months after that filing deadline (June 29, 2008) those financial statements have not been filed, the Alberta and British Columbia Securities Commissions may impose an Issuer Cease Trade Order against the Corporation. In addition, an Issuer Cease Trade Order may be imposed sooner if the Corporation fails to file its Default Status Reports on time. The Corporation intends to file Default Status Reports every two weeks for so long as it remains in default of filing its financial statements.

There is no other material information concerning the affairs of the Corporation that has not been generally disclosed.

**About Immunall Science Inc.**

Immunall Science Inc. (ISI) has a patented process for extracting certain components from American ginseng which have been shown to strengthen the immune system in humans and animals. The product ginsē (pronounced jin’ say) will be marketed to companies for inclusion in current products as a value added ingredient or as a new stand-alone product.

**THE CNQ EXCHANGE, INC. HAS NOT REVIEWED AND DOES NOT ACCEPT  
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE**

For further information: M. Frank Phillet, Chief Operating Officer  
Tel: (780) 718-6603 Fax: (780) 421-9262, Email: frank.phillet@ginse.ca